Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Advisory OTCs? GSK Discusses “Third Class” Drug Paradigm, But Xenical Not Included

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK Consumer Healthcare’s Regnier says firm is discussing pharmacy-only class internally but has yet to take a formal stance on the issue. Any switch of the weight-loss drug orlistat would occur within the existing two-class system, the company says.

You may also be interested in...

Xenical Diabetes Risk Reduction Data Added To Labeling

Roche weight loss drug adds data from the XENDOS trial showing ability to delay onset of type 2 diabetes in obese patients with impaired glucose tolerance. Change could help Roche increase reimbursement for Xenical.

Savient Delays 10-Q Filing Due To Oxandrin Return Reserve Errors

The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts